First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.
Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A, Rathkopf DE, Attard G, Scher HI, de Bono J, Danila DC.
Bianchini D, et al. Among authors: mukherji d.
Br J Cancer. 2013 Nov 12;109(10):2579-86. doi: 10.1038/bjc.2013.619. Epub 2013 Oct 29.
Br J Cancer. 2013.
PMID: 24169353
Free PMC article.
Clinical Trial.